Abstract
Metabolic abnormalities are emerging as an active driver to the development, progression and metastasis of various tumors. In the recent issue of the EMBO Journal, Yang and colleagues identified that succinylacetone (SA) could act as an oncometabolite and that accumulation of SA activates the NRF2/IGF1R axis in hepatocellular carcinoma (HCC) development. These discoveries not only yield great insights in the understanding of tumor biology, but also hold significant clinical ramifications, as these findings may pave a new way for the early diagnosis and treatment of HCC.
| Original language | English |
|---|---|
| Pages (from-to) | 333-334 |
| Number of pages | 2 |
| Journal | Genes and Diseases |
| Volume | 6 |
| Issue number | 4 |
| DOIs |
|
| State | Published - Dec 2019 |
Bibliographical note
Publisher Copyright:© 2019 Chongqing Medical University
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Genetics(clinical)
- Cell Biology
Fingerprint
Dive into the research topics of 'Oncometabolite modification of Keap1 links GSTZ1 deficiency with cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver